KENILWORTH, N.J.–(BUSINESS WIRE)–Merck (NYSE:MRK), known as MSD outside the United States and Canada, proudly congratulates William C. Campbell (pictured/Reuters/Brian Snyder), a retired scientist from Merck Research Laboratories, who was jointly named the 2015 Nobel Prize winner in Physiology or Medicine with Satoshi Omura for the discovery of avermectin, which led to Merck’s development of Mectizan (ivermectin), a treatment for river blindness (also known as onchocerciasis) in Africa, Latin America and Yemen.
Country efforts supported by a major public-private partnership—including The Carter Center/OEPA, PAHO/WHO, and Merck & Co., Inc.’s Mectizan Donation Program—bring the region closer to achieving the elimination goal by 2020.
Provision of safe water, sanitation and hygiene is one of the five key interventions within the global NTD roadmap. This strategy aims to mobilise WASH and NTD actors to work together towards the roadmap targets.
May 14, 2015—On May 14, 2015, the World Bank Group and PLOS Neglected Tropical Diseases launches a collection of peer-reviewed articles on the history and success of the control of river blindness (onchocerciasis) in Africa that started with the Onchocerciasis Control Program (OCP) in 1974 and transitioned into the African Program for Onchocerciasis Control (APOC) in 1995.
Scientists from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, and the University of California, Berkeley, and colleagues have developed a mobile phone microscope to measure blood levels of the parasitic filarial worm Loa loa.
Ce guide a été conçu pour enseigner aux membres du personnel des programmes nationaux
d’élimination de la FL, notamment le personnel de santé aux niveaux régional et de district, les
éléments essentiels des programmes nationaux de suivi et d’évaluation pour l’élimination de la FL.